SLS
SLS Stock July Rout Deepens: Pharma Bro Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas
Article Summary
HOLD- SELLAS Life Sciences (NASDAQ: SLSL) fell sharply after former hedge fund manager Martin Shkreli raised doubts about the timing of the Regal AML trial, saying he was not sure data would arrive this summer and suggested data could be delayed until Christmas.
- SELLAS Life Sciences Group has reached 78 of 80 events needed to trigger Regal's final analysis, bringing it closer to the most important clinical readout in its history.
- CEO Angelos Stergiou said the company is nearing the 80-event threshold, has entered a quiet period, and is focused on database lock.
- The Phase 3 trial is evaluating GPS as maintenance therapy for AML patients in second complete remission, with GPS extending median overall survival to 12.6 months compared with 8 months with standard treatment.
- The bearish thesis argues control patients may live longer than expected, raising the bar for statistical significance.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 127.6% | 20% | 100.0 ptsMassive Upside (127.6%) - Target: $27.50 vs Current: $12.08 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -23.9% | 15% | 40.0 ptsMild Pullback (-23.9%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About SLS
- SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
- The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
- SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.